Status:
COMPLETED
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Children's Hospital Medical Center, Cincinnati
Conditions:
Acute Kidney Injury
Nephrotoxicity
Eligibility:
All Genders
Up to 1 years
Brief Summary
Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of cases. Through initial ...
Detailed Description
Nephrotoxic medication-induced acute kidney injury (NTM-AKI) is a relevant yet underdiagnosed morbidity in the neonatal intensive care unit (NICU). Up to 87% of very low birth weight infants are expo...
Eligibility Criteria
Inclusion
- all NICU inpatients under 1 year of age; greater than 4 days of age that are
- Receiving 3 or more nephrotoxic medications on the same day OR
- Receiving 3 or more days of an intravenous aminoglycoside or vancomycin
Exclusion
- Less than 4 days of age
- Currently being treated for a urinary tract infection
- Presence of an acute kidney injury prior to enrollment
Key Trial Info
Start Date :
January 28 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT04354467
Start Date
January 28 2019
End Date
December 30 2023
Last Update
January 5 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's of Alabama
Birmingham, Alabama, United States, 35233
2
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229